PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit writes about the key takeaways from the ASCO 2025 Annual ...

Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and ...

Two out of every five Americans will be diagnosed with cancer in their lifetime. These are sobering statistics that remind us why investment in cancer research is so critically important for saving ...

Editor’s note: In this heartfelt interview, Jaylen Baron shares the story of her mother, Jane – an inspiring dance teacher, mentor and fighter – whose legacy is honored every year at PanCAN ...

Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights about the latest news ...

The U.S. Food and Drug Administration has granted accelerated approval for a new drug targeting a tumor alteration called NRG1 gene fusion found in roughly 3% of patients with pancreatic ...

A device already approved to treat several other types of cancer has shown positive results for a subset of patients with pancreatic cancer. In a Phase III clinical trial, a therapy known as Tumor ...

Read this story in English. Nota del editor: Durante el mes de la herencia hispana, que corre desde el 15 de Septiembre hasta el 15 de Octubre, estamos destacando nuestros servicios gratuitos y ...

For the first time in more than a decade, the FDA has approved a new first-line treatment for patients with metastatic pancreatic cancer. After a clinical trial showed a positive survival benefit, the ...

For the third year in the row, the five-year survival rate for pancreatic cancer has increased one percentage point, according to the American Cancer Society’s Cancer Facts & Figures 2024 Report ...

Despite advances in pancreatic cancer the disease is on track to become the second-leading cause of cancer-related deaths before 2030 LOS ANGELES, Calif. – (January 17, 2024) – The five-year survival ...

Happy New Year! I am excited to share with you an update about Precision Promise, our adaptive clinical trial platform that is sponsored by PanCAN and was developed to accelerate new treatments for ...